BAFF - an essential survival factor for B cells: Links to genesis of ITP and may be of therapeutic target

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 40-42

  Yu, Hui ming ^a,b   Liu, Yun fang ^b   Hou, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAFF PROTEIN; CELL PROTEIN; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; THROMBOCYTE ACTIVATION;

B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SIGNAL TRANSDUCTION;

EID: 36348942848     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.05.005     Document Type: Article

References (22)

1. Emmerich F., Bal G., Barakat A., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 136 (2007) 309-314
2. Koene H.R. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. Pediatr Blood Cancer 47 Suppl 5 (2006) 703-705
3. Reyes S.L.I., Leon B.F., Rozas V.M.F., Gonzalez J.P., and Naves P.R. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 134 (2006) 1175-1184
4. Matsushita T., Hasegawa M., Matsushita Y., et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 16 (2007) 87-93
5. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 (2006) 1933-1948
6. Bosello S., Pers J.O., Rochas C., et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 20 (2007) 1-8
7. Szodoray P., and Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 62 (2005) 421-428
8. George J.N. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4 (2006) 1664-1672
9. Yamanishi S., Iizumi T., Watanabe E., et al. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect Immun 74 (2006) 248-256
10. Hasler P., and Zouali M. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin Ther Targets 10 (2006) 803-815
11. Hou M., Lv B., He Q., et al. Both splenic CD5(+) B and CD5(-) B cells produce platelet glycoprotein-specific autoantibodies in chronic ITP. Thromb Res 110 (2003) 1-5
12. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 37 (2000) 239-248
13. Cines D.B., McKenzie S.E., and Siegel D.L. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 25 Suppl 1 (2003) S52-S56
14. Franchini M., Veneri D., Lippi G., and Stenner R. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 96 (2006) 119-125
15. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
16. Schneider P., MacKay F., Steiner V., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189 (1999) 1747-1756
17. Mackay I.R., Groom J., and Mackay C.R. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35 (2002) 551-553
18. Schneider P., and Tschopp J. BAFF and the regulation of B cell survival. Immunol Lett 88 (2003) 57-62
19. Mackay F., and Mackay C.R. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 23 (2002) 113-115
20. O'Connor B.P., Raman V.S., Erickson L.D., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199 (2004) 91-98
21. Enzler T., Bonizzi G., Silverman G.J., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25 (2006) 403-415
22. Zhang H.G., Yang P., Xie J., et al. Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J Immunol 168 (2002) 4164-4172